Reference
1. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
PREVYMIS™
(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL
Clinical Data for PREVYMIS™ (letermovir)
A pivotal, phase 3 study
Cytomegalovirus (CMV) prophylaxis was assessed in a randomized, multicenter, double-blind, placebo-controlled, pivotal, phase 3 study of adult CMV-seropositive recipients [R+] of allogeneic hematopoietic stem cell transplant (HSCT). Patients were randomized 2:1 to PREVYMIS or placebo and stratified by study site and high vs low risk (N=565).
(a) When coadministered with cyclosporine, the dose of PREVYMIS was decreased to 240 mg once daily, oral or IV infusion.
1. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Drug interactions may occur based on results from studies. Drug interactions may also occur based on predicted interactions. Potentially significant drug interactions include, but are not limited to, the following (information below applies to co-administration of PREVYMIS and the concomitant drug without cyclosporine, unless otherwise indicated):
Before prescribing PREVYMIS, please read the accompanying Prescribing Information. The Patient Information also is available.